Accolade (NASDAQ:ACCD) Shares Gap Down After Analyst Downgrade

Accolade, Inc. (NASDAQ:ACCD) gapped down before the market opened on Friday after Morgan Stanley lowered their price target on the stock from $13.00 to $12.00. The stock had previously closed at $9.19, but opened at $7.87. Morgan Stanley currently has an equal weight rating on the stock. Accolade shares last traded at $8.19, with a volume of 200,076 shares.

Several other analysts have also recently weighed in on ACCD. Needham & Company LLC dropped their price objective on shares of Accolade from $17.00 to $13.00 and set a “buy” rating for the company in a research note on Friday. Raymond James lifted their price objective on shares of Accolade from $12.00 to $16.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 9th. Wells Fargo & Company lifted their price objective on shares of Accolade from $10.00 to $12.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 9th. William Blair reiterated an “outperform” rating on shares of Accolade in a research note on Tuesday, January 9th. Finally, Truist Financial dropped their price objective on shares of Accolade from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Friday. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $14.80.

Institutional Investors Weigh In On Accolade

Institutional investors have recently added to or reduced their stakes in the business. Nordea Investment Management AB grew its holdings in Accolade by 1.4% during the 3rd quarter. Nordea Investment Management AB now owns 106,764 shares of the company’s stock worth $1,148,000 after acquiring an additional 1,423 shares during the last quarter. HighTower Advisors LLC acquired a new position in shares of Accolade in the 3rd quarter worth approximately $2,354,000. Vanguard Group Inc. lifted its position in shares of Accolade by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 5,283,858 shares of the company’s stock worth $55,903,000 after purchasing an additional 157,464 shares during the period. Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of Accolade by 111.1% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,798,993 shares of the company’s stock worth $19,033,000 after purchasing an additional 946,970 shares during the period. Finally, Olympiad Research LP acquired a new position in shares of Accolade in the 3rd quarter worth approximately $171,000. 84.99% of the stock is owned by institutional investors.

Accolade Stock Down 14.1 %

The stock has a market cap of $610.76 million, a price-to-earnings ratio of -5.93 and a beta of 2.08. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 0.48. The stock’s 50-day moving average price is $9.66 and its 200-day moving average price is $9.92.

Accolade (NASDAQ:ACCD) last released its earnings results on Thursday, April 25th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. Accolade had a negative net margin of 24.09% and a negative return on equity of 22.57%. The company had revenue of $124.80 million for the quarter, compared to the consensus estimate of $123.91 million. During the same quarter in the previous year, the company earned ($0.42) EPS. Accolade’s quarterly revenue was up 26.1% compared to the same quarter last year. On average, sell-side analysts expect that Accolade, Inc. will post -1.2 earnings per share for the current year.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.